News

Yahoo Finance1mon
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy - Yahoo Finance
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...
STAT2mon
5 questions for Boehringer Ingelheim’s new U.S. Human Pharma President
Brian Hilberdink, President, U.S. Human Pharma, Boehringer Ingelheim Brian Hilberdink, a pharmaceutical industry veteran, recently assumed the role of ...
FierceBiotech2y
Boehringer puts down $481M to pursue emerging cancer target - Fierce Biotech
Boehringer Ingelheim has spied an opportunity to seize the holy grail of immuno-oncology: turning cold tumors hot. In return for $10 million upfront and up to $471 million milestones, the German ...
Morningstar1mon
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy | Morningstar
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...